ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Lupus nephritis"

  • Abstract Number: 1841 • ACR Convergence 2025

    Differential metabolomic signatures along lupus nephritis spectrum

    Mariana Jiménez Tirado1, karina santana2, Jiram Torres Ruiz3, Jennifer Tiaré Balderas Miranda4, Diana Gómez-Martín5, José Carlos Páez Franco6, Nancy R Mejía Domínguez7, Hilda Sánchez Vidal6 and Imelda Cecilia Zarzoza Mendoza8, 1Instituto Nacional de Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 2INCMNSZ, Ciudad de México, Federal District, Mexico, 3INCMNSZ, Mexico, Federal District, Mexico, 4Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 5INCMNSZ, Mexico city, Federal District, Mexico, 6Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Distrito Federal, Mexico, 7Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 8Red de Apoyo a la Investigación, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán and Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico

    Background/Purpose: Lupus nephritis (LN) is a common feature in systemic lupus erythematosus (SLE) affecting up to 50% of the individuals with this disease. The gold…
  • Abstract Number: 1520 • ACR Convergence 2025

    Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis

    Bahtiyar Toz1, Himanshu Vashistha2 and Richard Furie3, 1Zucker School of Medicine at Hofstra/ Northwell, Queens, NY, 2Northwell Health, Great Neck, NY, 3Division of Rheumatology, Northwell Health, Great Neck, NY

    Background/Purpose: Biologic treatments for lupus nephritis (LN) have improved short-term outcomes. Obinutuzumab (OBI), an anti-CD20 monoclonal antibody, demonstrated efficacy in the NOBILITY and REGENCY trials;…
  • Abstract Number: 0945 • ACR Convergence 2025

    Nerve Injury-Induced Protein-1 (Ninj1) Deficiency Aggravates Murine Lupus Through Modulation of Macrophage Polarization

    Jorge Romo-Tena1, Luz Blanco2, Shuichiro Nakabo3, Victoria Hoffman4, Norio Hanata5, Mingzeng Zhang2, Carmelo Carmona-Rivera5, Eduardo Patino-Martinez6, Dillon Claybaugh2, Zu-Xi Yu2 and Mariana Kaplan5, 1Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2NIH, Bethesda, MD, 3NIAMS, NIH, Bethesda, MD, 4Diagnostic and Research Services Branch, Division of Veterinary Resources, Office of Research Services, National Institutes of Health, Bethesda, MD, Bethesda, 5Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, Bethesda, MD, 6NIH/NIAMS, Bethesda, MD

    Background/Purpose: Nerve injury-induced protein-1 (Ninj1) is an adhesion molecule that plays various roles in immune and stromal cells, including the modulation of inflammation and a…
  • Abstract Number: 0639 • ACR Convergence 2025

    Kidney Transplantation In Lupus Nephritis. Multicenter Study Of 103 Patients

    Vanesa Calvo-Río1, Lara Sánchez Bilbao1, Carmen Secada-Gómez1, Paúl Hernández Velasco2, Celia González-García3, Enrique Morales4, María Galindo-Izquierdo5, Sebastián Sandoval-Moreno6, Josefina Cortés-Hernández7, César Antonio Egües Dubuc8, Niccolo Viveros-Pérez9, María Caeiro10, Adrián Mayo-Juanatey11, Miriam Retuerto Guerrero12, María Camila Osorio-Sanjuan13, Luis Sala14 and Ricardo Blanco1, 1Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain, Santander, Cantabria, Spain, 2Nephrology, Hospital Universitario 12 de Octubre, Madrid. Spain, Madrid, Madrid, Spain, 3Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 4Nephrology, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, 5Department of Rheumatology, Hospital Universitario 12 de Octubre, Madrid, Spain, Madrid, Madrid, Spain, 6Hospital Universitario Vall D'Hebron, Barcelona, Spain, 7Hospital Universitari Vall d’Hebron-Universitat Autónoma de Barcelona, Barcelona, Spain, 8Donostia University Hospital, San Sebastián, Pais Vasco, Spain, 9Hospital Universitario Germans Trias i Pujol, Badalona, Spain, 10Centro Hospitalario Universitario de Pontevedra, Pontevedra, Spain, 11Hospital Universitario Doctor Peset, Valencia, Comunidad Valenciana, Spain, 12Complejo Asistencial Universitario de León, Leon, Castilla y Leon, Spain, 13Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, 14Hospital Universitario de Torrejón, Madrid, Spain

    Background/Purpose: Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) affecting to 40-60% of SLE. End-stage renal disease (ESRD) occurs in up…
  • Abstract Number: 0839 • ACR Convergence 2025

    Precision Liquid Biopsy for Lupus Nephritis: cfDNA Methylation and Fragmentomic Signatures Enable Non-Invasive Diagnosis and Dynamic Disease Tracking

    Qiuyu Jing1, Qiang Li2, Chiu Wai Shirley Chan3, Weixin Chen4, Fung Yu Nick choi4, Iris Tang5, Chak Sing Lau6, Heidi Ling6, Jason Wong7 and Philip Li2, 1Center for Oncology & Immunology, Hong Kong, Hong Kong, 2Department of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, 3Division of Rheumatology and Clinial Immunology, Department of Medicine, the University of Hong Kong, Hong Kong, Hong Kong, China, 4School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong, 5Department of Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, Hong Kong, 6The University of Hong Kong, Hong Kong, Hong Kong, 7School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hing Kong, Hong Kong

    Background/Purpose: Lupus nephritis (LN), a severe complication of systemic lupus erythematosus (SLE), lacks reliable non-invasive biomarkers for early detection and monitoring. This study investigates plasma…
  • Abstract Number: PP08 • ACR Convergence 2025

    Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient

    Matt Makara, Casey Hogan

    Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…
  • Abstract Number: 2427 • ACR Convergence 2025

    Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease

    Sepehr Taghavi1, Ines Silva2, Jacob Vasquez3, Vasileios Kyttaris4, Tyler O'Malley5 and Mike Nerenberg6, 1Exagen Inc, Escondido, CA, 2Exagen, Carlsbad, CA, 3Exagen, Inc., Vista, CA, 4Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 5Exagen, Vista, CA, 6Exagen, DEL MAR, CA

    Background/Purpose: Early detection of renal involvement in diabetic kidney disease (DKD) and lupus nephritis (LN) is critical but remains challenging. Conventional renal biomarkers (serum creatinine,…
  • Abstract Number: 1836 • ACR Convergence 2025

    Emerging Role of B Cell Subtype-Specific Intracytoplasmic Toll-Like Receptor Expression and Serum Eotaxin as Biomarkers in Lupus Nephritis

    Jennifer Tiaré Balderas Miranda1, Yatzil Reyna Juárez2, Beatriz Alcalá-Carmona3, Nancy R Mejía Domínguez4, María José Ostos Prado3, José Luis Maravillas-Montero5, Fabiola Cassiano-Quezada6, Guillermo Juárez Vega4, karina santana7, Jiram Torres Ruiz8 and Diana Gómez-Martín9, 1Universidad Nacional Autónoma de México, Coyoacán, Federal District, Mexico, 2Instituto Politècnico Nacional, Tultitlán de Mariano Escobedo, Mexico State, Mexico, 3Instituto Nacional De Ciencias Médicas Y Nutrición Salvador Zubirán, Mexico City, Distrito Federal, Mexico, 4Universidad Nacional Autónoma de México, Mexico City, Distrito Federal, Mexico, 5Red de Apoyo a la Investigación, Universidad Nacional Autónoma de México, Tlalpan, Distrito Federal, Mexico, 6Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, Mexico, 7INCMNSZ, Ciudad de México, Federal District, Mexico, 8INCMNSZ, Mexico, Federal District, Mexico, 9INCMNSZ, Mexico city, Federal District, Mexico

    Background/Purpose: B cells play an essential role in lupus nephritis (LN) pathogenesis. However, abnormalities in specific subtypes like age-associated B cells (ABCs) and double negative…
  • Abstract Number: 1517 • ACR Convergence 2025

    The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters

    Aijing Liu1, Fei Chang2 and Qiuhong Xu1, 1Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), 2Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic)

    Background/Purpose: Lupus nephritis (LN), affects 30%-50% of systemic lupus erythematosus (SLE) patients, a major contributor to SLE-related mortality. Telitacicept, an innovative recombinant fusion protein, disrupts…
  • Abstract Number: 0944 • ACR Convergence 2025

    L-sepiapterin treatment reduces renal cortical gene expression associated with oxidative stress and fibrosis in NZM2410 murine lupus nephritis

    Dayvia Russell1, Soroush Moradi2, Suganya Subramanian2, Silvia Vaena2, Sandra Mungaray2, Stanley Hoffman2, Stefano Berto2 and Jim Oates2, 1Ralph H. Johnson VA, Charleston, SC, 2Medical University of South Carolina, Charleston, SC

    Background/Purpose: Systemic lupus erythematosus (SLE) is a disease of endothelial (EC) dysfunction. We hypothesize that much of this dysfunction stems from uncoupling of endothelial nitric…
  • Abstract Number: 0636 • ACR Convergence 2025

    AA Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways

    Sepehr Taghavi1, Ines Silva2, Jacob Vasquez3, Vasileios Kyttaris4, Tyler O'Malley5 and Mike Nerenberg6, 1Exagen Inc, Escondido, CA, 2Exagen, Carlsbad, CA, 3Exagen, Inc., Vista, CA, 4Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, 5Exagen, Vista, CA, 6Exagen, DEL MAR, CA

    Background/Purpose: Lupus nephritis (LN) and diabetic kidney disease (DKD) are leading causes of chronic kidney disease (CKD) that differ by age, sex, and underlying mechanisms.…
  • Abstract Number: 0838 • ACR Convergence 2025

    Complete Renal Response and Long-Term, Progression-Free Survival in Adult Patients With Lupus Nephritis: A Retrospective Cohort Study in the United States

    Lisa Lindsay1, Shu Wang2, Huong Trinh1, Yunru Huang1, William Pendergraft1 and Brad Rovin3, 1Genentech, Inc., South San Francisco, CA, 2Genesis Research LLC, Hoboken, NJ, 3The Ohio State University, Columbus, OH

    Background/Purpose: Complete renal response (CRR) and flare prevention, as early markers of long-term kidney survival, are important outcomes in lupus nephritis (LN) clinical trials.Methods: This…
  • Abstract Number: 2697 • ACR Convergence 2025

    A Prospective Randomized Controlled 96-week Study to Evaluate the Efficacy and Safety of Tacrolimus and Glucocorticoid as Continuous Induction-Maintenance Treatment for Class III/IV±V Lupus Nephritis

    Sandra Navarra1, Desmond Yat-Hin Yap2, Zhaohui Ni3, Yingyos Avihingsanon4, Soo Kun Lim5, Na Jiang3, Wei Chen6, Chao Li7, Helen Zhi8, Chenzhu Zhang9, Catherine Chan2, Susan Yung2, Tsutomu Takeuchi10 and Tak Mao Daniel Chan2, 1University of Santo Tomas, Manila, Philippines, 2Department of Medicine, The University of Hong Kong, Hong Kong SAR, Hong Kong, 3Renji Hospital, Shanghai Jiao Tong University, School of Medicine, Shanghai, China (People's Republic), 4King Chulalongkorn Memorial Hospital, Chulalongkorn University, Bangkok, Thailand, 5Department of Medicine, University Malaya Medical Centre, Kuala Lumpur, Malaysia, 6Department of Nephrology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China (People's Republic), 7Department of Nephrology, Peking Union Medical College Hospital, Beijing, China (People's Republic), 8School of Public Health, The University of Hong Kong, Hong Kong SAR, Hong Kong, 9Department of Medicine, University of Hong Kong-Shenzhen Hospital, Shenzhen, China (People's Republic), 10Saitama Medical University and Keio University, Tokyo, Japan

    Background/Purpose: Tacrolimus (TAC) and glucocorticoid as continuous induction-maintenance therapy for lupus nephritis (LN) has never been investigated. We conducted a prospective randomized open-label multicenter study…
  • Abstract Number: 2421 • ACR Convergence 2025

    Whole Blood Immune Phenotyping Reveals Cytometric Differences in B Cell Clusters Between Lupus Nephritis and Non-Lupus Nephritis SLE Patients with Minimal Proteinuria

    Nicholas Bauer1, Philip Carlucci2, Rufei Lu1, Carla Guthridge1, Tayte Stephens3, Benjamin Jones4, Wade DeJager5, Susan Macwana1, Andrea Fava6, Sanchit Sanyal7, Erin Carter8, Mala Masson9, Jennifer Anolik10, Jennifer Barnas11, Peter Izmirly12, H Michael Belmont13, Kelly Ruggles14, Study Team ALE06 Clinical1, Brad Rovin15, Jill Buyon16, Michelle Petri17, Judith James1 and Joel Guthridge1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2New York University School of Medicine, New York, NY, 3University of Oklahoma Health Science Center, Oklahoma City, OK, 4Oklahoma State University, Oklahoma City, OK, 5Oklahoma Medical Research Foundation, Oklahoma City, 6Johns Hopkins University, Baltimore, MD, 7Johns Hopkins University School of Medicine, Baltimore, MD, 8New York University Grossman School of Medicine, New York, NY, 9NYU Langone Medical Center- Division of Rheumatology, New York, NY, 10University of Rochester Medical Center, Rochester, NY, 11University of Rochester, Rochester, NY, 12New York University Grossman School of Medicine, New York, NY, 13NYU School of Medicine, New York, NY, 14NYU Grossman School of Medicine, Brooklyn, NY, 15The Ohio State University, Columbus, OH, 16NYU Grossman School of Medicine, New York, NY, 17Johns Hopkins University School of Medicine, Timonium, MD

    Background/Purpose: Autoreactive B cell populations play a key role in the pathogenesis of lupus nephritis (LN). Therefore, it is hypothesized that dysregulation in the B…
  • Abstract Number: 1835 • ACR Convergence 2025

    Serum Zonulin As A Biomarker Of Renal Involvement In Systemic Lupus Erythematosus: Shedding Light On The Gut-Kidney Axis

    Alessandra Milone1, Giulio Forte2, Alessia Salzillo2, Barbara De Marino2, Rosa Giacca2, Francesco Ciccia3 and Daniele Mauro4, 1University of Campania L. Vanvitelli, Naples, 2University of Campania L. Vanvitelli, Naples, Italy, 3Rheumatology Section, University of Campania L. Vanvitelli, Naples, Italy, Naples, Italy, 4University of Campania, Italy, Naples, Italy

    Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease in which lupus nephritis (LN) remains a major cause of morbidity and mortality. Zonulin, a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 44
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology